The goal of this clinical research study is to learn if azacitidine combined with Chidamide will help to control the disease in patients with high-risk AML after an allogeneic stem cell transplant. The safety of this combination will also be studied.
1.Age 18 to 60 years old,both male and female
2.Be able to understand and sign informed consent
3.Patients with a diagnosis of AML not M3 according to the 2016 World Health Organization (WHO) Acute Myeloid Leukemia Classification and Diagnostic
4.Patients have AML with poor genetic abnormalities,primary refractory AML,relapsed AML or secondary AML
1.Uncontrollable active infection
2.Patients with active hepatitis B or C or HIV infection before enrollment
3.Have a grade III-IV graft-versus-host disease